FDA Approves Gene Therapy for Certain Types of Non-Hodgkin Lymphoma

By October 19, 2017

Yescarta, a CD19-directed genetically modified autologous T cell immunotherapy, is indicated for use in large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Antibiotics May Reduce Infection Risk Post-Colorectal CA Surgery

October 19, 2017

The researchers found that patients who received oral antibiotics and MBP had a lower overall SSI rate than those who received MBP only (8 versus 27%; P=0.03).

'Widely Divergent' Beliefs Across U.S. Regarding Thyroid Nodules, CA

October 13, 2017

There was a 6.2-fold difference in thyroidectomy rates across U.S. regions (range, 22 to 139 per 100,000 Medicare beneficiaries).

Study IDs Neurotoxicity Following CD19 CAR-T Cells Infusion

October 12, 2017

The researchers found that there were correlations for acute lymphoblastic leukemia, high CD19+ cells in bone marrow, high CAR-T cell dose, cytokine release syndrome, and pre-existing neurologic comorbidities with elevated risk of neurologic adverse events.

NDA Submitted for Novel Non-Metastatic CRPC Treatment

By October 11, 2017

Apalutamide, an investigational, next generation oral androgen receptor inhibitor, was assessed for safety and efficacy in the Phase 3 pivotal trial, ARN-509-003 (SPARTAN), which the NDA is based on.

USPSTF Issues Draft Recommendation on Counseling to Prevent Skin Cancer

October 11, 2017

The researchers recommend that clinicians provide counseling on sun protection behaviors for anyone with fair skin aged 6 months to 24 years, including parents of young children with fair skin (B recommendation).

PLK1 Inhibitor Granted Orphan Drug Designation for AML

By October 10, 2017

A Phase 1b/2 open-label study is being planned to assess the safety and efficacy of PCM-075.

Do SGLT2 Inhibitors Increase Cancer Risk in T2D Patients?

October 06, 2017

Overall cancer risk not increased compared with placebo, other active glucose-lowering treatments

Case: Tattoo Ink-Induced Lymphadenopathy Misdiagnosed as Cancer

October 04, 2017

Case report describes patient with multiple enlarged lymph nodes seen on PET-CT years after tattoo

FDA Approves New Alunbrig Tablet Strength

By October 03, 2017

The FDA granted accelerated approval of Alunbrig, a kinase inhibitor, for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Do Checkpoint Inhibitors Carry Endocrine Dysfunction Risk?

September 29, 2017

Combination does not increase immune-related adverse events in metastatic lung cancer patients

Can β-Blocker Use Protect Against Melanoma Recurrence?

September 29, 2017

The researchers found that the use of propranolol at the time of diagnosis was significantly inversely linked to melanoma recurrence after adjustment for known prognostic factors, with about an 80% reduction in risk for propranolol users.

FDA Approves Verzenio for Advanced or Metastatic Breast Cancer

By September 28, 2017

Verzenio is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6).

Potential Prognostic Biomarker ID'd for Triple-Negative Breast CA

September 26, 2017

African-American patients harbored significantly more tumor-infiltrating lymphocytes than European Americans among early-stage (I to II), but not late-stage (III to IV), patients.

Opdivo OK'd for Hepatocellular Carcinoma in Previously Treated Adults

By September 25, 2017

The overall response rate based on modified RECIST was 18.2% with complete response rate of 3.2% and partial response rate of 14.9%.

Keytruda Gains Additional Use in Advanced Gastric Cancers

By September 25, 2017

The overall response rate among patients was 13.3% (95% CI: 8.2, 20.0) with a complete response seen in 1.4% and partial response in 11.9%.

Treatment for Subtype of T-Cell Lymphoma Granted Breakthrough Designation

By September 20, 2017

The study enrolled a total of 372 patients with MF and SS who were randomized to either receive mogamulizumab or vorinostat.

Histamine-Producing Probiotic Shows Promise in Treating Colorectal CA

September 20, 2017

The researchers found that administration of hdc+ Lactobacillus reuteri in the gut resulted in luminal hdc gene expression and production of histamine in the intestines of Hdc−/− mice.

Weight May Play Role in Selecting Treatment Strategy for Breast CA Patients

September 20, 2017

BMI was positively correlated with ER+/PR+ and ER−/PR− subtype risks, with a significant association only seen for ER+/PR+ subtypes.

FDA Approves Somatuline Depot to Treat Carcinoid Syndrome

By September 18, 2017

The 16-week study (n=115) enrolled patients with histopathologically-confirmed neuroendocrine tumors and a history of carcinoid syndrome who were treatment-naive or stable on another somatostatin analog.

Aliqopa Approved for Relapsed Follicular Lymphoma

By September 14, 2017

Results from the trial showed that 59% of patients had a complete or partial response for a median 12.2 months.

First Biosimilar For Cancer Treatment Approved

By September 14, 2017

The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.

Multivitamins Tied to Reduced Risk of Chemo-Induced Neuropathy

September 13, 2017

The researchers found that there was an association for multivitamin use before diagnosis with reduced symptoms of CIPN (CTCAE-adjusted odds ratio, 0.6 [95% confidence interval, 0.42 to 0.87]; FACT/GOG-Ntx-adjusted OR, 0.78 [95% confidence interval, 0.61 to 1]).

USPSTF: Cervical Cancer Screening Recommendations Issued

September 13, 2017

For women aged 21 to 29 years, the USPSTF recommends screening for cervical cancer with cervical cytology alone every 3 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone or every 5 years with hrHPV testing alone (A recommendation).

Cabometyx sNDA Submitted for Expanded Renal Cell Carcinoma Indication

By September 13, 2017

"If [the sNDA is] approved, Cabometyx will offer an important new alternative for the treatment of patients with previously untreated advanced RCC," said Michael M. Morrissey, PhD, President and CEO of Exelixis.

Airplane Medical Emergencies: Is it a Physician's Duty to Help?

September 13, 2017

In the United States, Canada, and United Kingdom, physicians do not have the legal duty to assist unless there is a prior patient-physician relationship.

BRAF, MEK Inhibitor Combo Assessed in Resected Melanoma

September 13, 2017

The researchers found that the estimated 3-year rate of relapse-free survival was 58% in the combination-therapy group and 39% in the placebo group at a median follow-up of 2.8 years.

Nivolumab vs. Ipilimumab as Adjuvant Tx in Resected Advanced Melanoma

September 12, 2017

The researchers found that the 12-month rate of recurrence-free survival was 70.5 and 60.8% in the nivolumab and ipilimumab groups, respectively, at a minimum follow-up of 18 months.

Anti-PD-1 Therapy Tied to Neurological Adverse Events

September 11, 2017

The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.

Survival Rates Compared for Durvalumab vs. Placebo in NSCLC

September 11, 2017

A significantly higher response rate was seen with durvalumab versus placebo (28.4 versus 16.0%), with a longer median duration of response (72.8 versus 46.8% of patients had ongoing response at 18 months).